Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
About this trial
This is an interventional diagnostic trial for Adult Anaplastic Astrocytoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed and/or clinical and imaging evidence of a de novo mass that is likely to be a brain tumor Amenable to debulking surgery or surgical resection or biopsy as standard initial therapy for the tumor Performance status - Karnofsky 70-100% At least 3 months WBC count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin < 1.2 mg/dL Creatinine < 1.3 mg/dL No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No other significant cardiac condition that would preclude study participation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 month after study participation Weight ≤ 130 kg No peripheral neuropathy ≥ grade 3 No history of allergic reaction attributed to metronidazole No other uncontrolled illness No psychiatric illness or social situation that would preclude study compliance No other medical condition that would preclude study participation
Sites / Locations
- Abramson Cancer Center of The University of Pennsylvania
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group 1 (fluorine F 18 EF5, PET)
Group 2 (EF5, PET)
Group 3 (EF5, PET)
Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.